Ocular Complications of Checkpoint Inhibitors and Immunotherapeutic Agents: A Case Series

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Ophthalmologists have a role in assessing immune-related adverse events (IRAE) in oncology patients on immunotherapy. We assessed the utility of a hospital-wide toxicity team in referring patients with new ocular symptoms for examination. We also identified new immunotherapy agents causing ocular side-effects. Design: A cohort study of eight consecutive patients on immunotherapy, who developed ocular IRAE from November 1, 2017 to June 30, 2019. All were seen at the Ocular Immunology Division of the Wilmer Eye Institute and referred by the Johns Hopkins Toxicity Team. Results: All eight patients on had IRAEs; were treated with corticosteroid drops or observation with clinical resolution. Two new agents, epocadostat and daratumumab, were associated with the development of uveitis. Conclusion: Ophthalmologists play an important role in a hospital-wide toxicity team and need to include IRAEs in their differential diagnosis. Given new drug development, ophthalmologists may be the first to identify IRAEs.

Original languageEnglish (US)
Pages (from-to)1-6
Number of pages6
JournalOcular Immunology and Inflammation
DOIs
StatePublished - 2020

Keywords

  • drug toxicity
  • immunotherapy
  • multidisciplinary coordination of care
  • ocular adverse events
  • Uveitis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Ophthalmology

Fingerprint Dive into the research topics of 'Ocular Complications of Checkpoint Inhibitors and Immunotherapeutic Agents: A Case Series'. Together they form a unique fingerprint.

Cite this